Approach to childhood asthma in the era of COVID-19

Al-Shamrani, Abdullah; Alharbi‎, Abdulrahman; Alhaider, Sami; Alharbi, Saleh; Alharbi, Nasser; Alanazi, Alnashmi; Ahmadi, Turki S. Al

doi:10.1016/j.ijpam.2020.07.001

Cited by 3 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SINA has released specific advices on asthma management of adult and children during the COVID-19 pandemic. [ 349 350 ] Expert SINA panel advises to continue routine care for patient with acute exacerbation of bronchial asthma and to follow the regular clinical guideline including early.…”

Section: Section 9: Management Of Asthma In Childrenmentioning

confidence: 99%

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2021

View full text Add to dashboard Cite

The Saudi Initiative for Asthma 2021 (SINA-2021) is the fifth version of asthma guidelines for the diagnosis and management of asthma for adults and children, which is developed by the SINA group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up to date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is aligned for age groups: adults, adolescents, children aged 5–12 years, and children aged less than 5 years. SINA guidelines have focused more on personalized approaches reflecting better understanding of disease heterogeneity with the integration of recommendations related to biologic agents, evidence-based updates on treatment, and the role of immunotherapy in management. Medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and the current situation at national and regional levels. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.

show abstract

Section: Section 9: Management Of Asthma In Childrenmentioning

confidence: 99%

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children

et al. 2021

View full text Add to dashboard Cite

show abstract

“…SINA expert panel has released specific advices on asthma management of adult and children during the COVID-19 pandemic. [ 356 357 ] SINA expert panel advice to continue routine care for patient with acute exacerbation of bronchial asthma and to follow the regular clinical guideline in the occasion of pandemics.…”

Section: Section 9: Asthma In Childrenmentioning

confidence: 99%

The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and children

Al-Moamary,

Alhaider,

Allehebi

et al. 2023

Annals of Thoracic Medicine

Self Cite

View full text Add to dashboard Cite

The Saudi Initiative for Asthma 2024 (SINA-2024) is the sixth version of asthma guidelines for the diagnosis and management of asthma for adults and children that was developed by the SINA group, a subsidiary of the Saudi Thoracic Society. The main objective of the SINA is to have guidelines that are up-to-date, simple to understand, and easy to use by healthcare workers dealing with asthma patients. To facilitate achieving the goals of asthma management, the SINA Panel approach is mainly based on the assessment of symptom control and risk for both adults and children. The approach to asthma management is aligned for age groups: adults, adolescents, children aged 5–12 years, and children aged <5 years. SINA guidelines have focused more on personalized approaches reflecting a better understanding of disease heterogeneity with the integration of recommendations related to biologic agents, evidence-based updates on treatment, and the role of immunotherapy in management. The medication appendix has also been updated with the addition of recent evidence, new indications for existing medication, and new medications. The guidelines are constructed based on the available evidence, local literature, and the current situation at national and regional levels. There is also an emphasis on patient–doctor partnership in the management that also includes a self-management plan.

show abstract

“…18 No. 3 Summer, 2023 IRANIAN JOURNAL OF PATHOLOGY 12,13,14). Seven strains of coronaviruses can cause diseases in humans; however, these strains mostly cause mild infections.…”

Section: Introductionmentioning

confidence: 99%

“…This is the largest genome within the RNA viruses, ranging from 26-32 kb (10,11,13,15). Familial clustering, demographic characteristics, exposure history, and other evidence have provided information on the virus's direct (personto-person) transmission (10,12). Compared to other severe coronavirus strains, such as SARS and MERS, that typically cause infections in humans, the mortality of COVID-19 is less (estimation of 4% for COVID-19 instead of 14-15% for SARS and 34% for MERS).…”

Section: Introductionmentioning

confidence: 99%

Comparative Analysis of 198 SARS-CoV-2 Genomes from Iran and West Asia, February 2020 to December 2021

karami,

Mojbafan,

Mazaheri Nezhad Fard

2023

Iran J Pathol

View full text Add to dashboard Cite

Background & Objective: Coronavirus disease 2019 (COVID‐19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in a worldwide pandemic. The first case of COVID‐19 was reported from Wuhan in the Hubei Province of China in December 2019; however, the disease's origin is still mysterious. Whole-genome sequence analysis is essential for monitoring the spread of infectious diseases as well as studying the pathogenesis and evolution of viruses. In this study, analysis of 198 fully sequenced genomes from Iran and West Asia was carried out to study mutations, phylogeny, amino acid changes, clades, and lineages of these genomes as well as comparison of these sequences with those of reference Wuhan genome of NC_045512.2. Methods: In total, 198 completely sequenced genome data from Iran and West Asia were collected from GenBank. Mutation detection was carried out using a trial version of CLC Genomics Workbench v.21.0 (QIAGEN, Germany). Online tools such as GISAID Mutations App and Pangolin were used for further analysis of the results. Results: In this study, several unique mutation sites were identified in the Iranian genomes ( n = 8); positions 1397 G>A and 29742 G>T were the most frequent changes in more than 85% of the Iranian genomes. Mutation rate, mutation per sequence, and transition versus transversion for the Iranian genomes included 4.73, 14.14, and 1.6, respectively. Generally, C>T alteration was the most common substitution in all the sequences. Conclusion: The ORF1ab, N, and S were the genes with the most changes. The current data can help researchers predict future epidemics and establish better strategies to control viral pandemics.

show abstract

Approach to childhood asthma in the era of COVID-19

Cited by 3 publications

References 33 publications

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children

The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children

The Saudi initiative for asthma – 2024 update: Guidelines for the diagnosis and management of asthma in adults and children

Comparative Analysis of 198 SARS-CoV-2 Genomes from Iran and West Asia, February 2020 to December 2021

Contact Info

Product

Resources

About